A placebo-controlled study of the doses and efficacy of <i>Lentinula edodes</i> mycelia for oxaliplatin-induced peripheral neuropathy in colorectal cancer.

Front Oncol · 2025 · PMC12376294 · PMID 40860821

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

a favorable trendp = 0.06so close (0.05 < p ≤ 0.1)

−10.69 [95% CI; −27.07 to 5.69]; p = 0.83); however, the high-dose group showed a favorable trend compared with the placebo group (−12.20 vs . −29.32 [95% CI; −53.4 to −5.2]; p = 0.06).

also in 466 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

A placebo-controlled study of the doses and efficacy of &lt;i&gt;Lentinula edodes&lt;/i&gt; mycelia for oxaliplatin-induced peripheral neuropathy in colorectal cancer.

The sentences

A placebo-controlled study of the doses and efficacy of <i>Lentinula edodes</i> mycelia for oxaliplatin-induced peripheral neuropathy in colorectal cancer.